Showing 4871-4880 of 20470 results for "".
- Digital Twin–Guided VT Ablation Shows Early Feasibilityhttps://reachmd.com/news/digital-twinguided-vt-ablation-shows-early-feasibility/2486513/Key Takeaways: A small NEJM-reported feasibility study (n=10) evaluated MRI-based “digital twin” simulations to guide VT ablation in post–myocardial infarction patients. Digital twin–derived targets were integrated into procedural navigation, with all
- GLP-1 Use Linked to Residual Gastric Content Before Anesthesiahttps://reachmd.com/news/glp-1-use-linked-to-residual-gastric-content-before-anesthesia/2486505/Key Takeaways: The study reports an association between GLP-1 receptor agonist use and increased prevalence of ultrasound-defined residual gastric content in fasted patients. Gastric content was assessed using standardized preinduction ultrasonography,
- Global Progress on Under-5 Mortality Remains Unevenhttps://reachmd.com/news/global-progress-on-under-5-mortality-remains-uneven/2486507/Key Takeaways: A modelling report projects that global progress toward SDG 3.2 may reach the target after 2030, with estimated attainment around 2035. Country-level projections indicate that while many countries have met or are on track to meet the tar
- AI Scribes Linked to Modest EHR Time Reductionshttps://reachmd.com/news/ai-scribes-linked-to-modest-ehr-time-reductions/2486514/Key Takeaways: AI scribe access was associated with modest reductions in EHR and documentation time (≈13–16 minutes per 8-hour session). Weekly visit volume increased slightly, while after-hours EHR time did not change significantly. Findings
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://reachmd.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20
- Endoscopic Assessment vs EUS in Superficial GI Neoplasia Staginghttps://reachmd.com/news/endoscopic-assessment-eus-staging-superficial-gi-neoplasia/2486487/Key Takeaways: Investigators reported higher overall accuracy for high-definition endoscopic assessment than for EUS in distinguishing intramucosal (HGD/T1a) lesions from deeper invasion when compared with final histology. EUS was described as prone to
- Nicotinamide Linked to Reduced Melanoma Risk in VA Cohorthttps://reachmd.com/news/nicotinamide-linked-to-reduced-melanoma-risk-in-va-cohort/2486445/Nicotinamide exposure was associated with a 25% reduction in melanoma incidence in a large VA cohort, according to data from a retrospective cohort study presented at the 2026 American Academy of Dermatology Annual Meeting. Investigators analyzed 30,741 pati
- Molecular Characterization of Colistin-Resistant A. baumanniihttps://reachmd.com/news/molecular-colistin-resistant-a-baumannii/2486486/Key Takeaways: Investigators report phenotypic colistin resistance confirmed using reference broth microdilution and gradient diffusion methods, with agreement against prior routine automated reporting. Across the resistant collection, the authors desc
- Case Report Describes Dual-Phase CL Code for Facial Rejuvenationhttps://reachmd.com/news/case-report-describes-dual-phase-cl-code-for-facial-rejuvenation/2486484/A case report in the April 2026 issue of Journal of Cosmetic Dermatology described a dual-phase injectable approach to facial rejuvenation that combined contour restoration with ligamentous support using a polycaprolactone-based collagen stimulator. The authors termed the method the “CL
- Nail Psoriasis and Real-World Data Highlight Tildrakizumab’s Staying Powerhttps://reachmd.com/news/nail-psoriasis-and-real-world-data-highlight-tildrakizumabs-staying-power/2486482/Two posters presented at the American Academy of Dermatology (AAD) Annual Meeting highlight both clinical trial efficacy and real-world durability of tildrakizumab, an interleukin (IL)-23 p19 inhibitor, in patients with moderate-to-severe plaque psoriasis.